Combination of Thrombolysis and Glycoprotein IIb/IIIa Inhibition in Chronic Peripheral Thrombosis: A Case Report

<p>Currently, many interventionalists employ either tissue plasminogen activator (alteplase, Genentech,San Francisco, CA), or recombinant plasminogen activator (reteplase, Chiesi USA, Inc., Cary, NC), for peripheral thrombolysis. Further, combination therapy utilizing a thrombolytic agent and...

Full description

Saved in:
Bibliographic Details
Main Authors: Mubin I Syed (Author), Ryan Gallagher (Author), Zeshan Hussain (Author), Azim Shaikh (Author), Philip J Cain (Author), Kamal Morar (Author), Matthew Sebastian (Author), Robert Tyrrell (Author), Allen Guehl (Author), Ronald Erdelyi (Author)
Format: Book
Published: International Journal of Radiology and Radiation Oncology - Peertechz Publications, 2017-01-24.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_ijrro_000020
042 |a dc 
100 1 0 |a Mubin I Syed  |e author 
700 1 0 |a  Ryan Gallagher  |e author 
700 1 0 |a  Zeshan Hussain  |e author 
700 1 0 |a  Azim Shaikh  |e author 
700 1 0 |a  Philip J Cain  |e author 
700 1 0 |a  Kamal Morar  |e author 
700 1 0 |a  Matthew Sebastian  |e author 
700 1 0 |a  Robert Tyrrell  |e author 
700 1 0 |a  Allen Guehl  |e author 
700 1 0 |a Ronald Erdelyi  |e author 
245 0 0 |a Combination of Thrombolysis and Glycoprotein IIb/IIIa Inhibition in Chronic Peripheral Thrombosis: A Case Report 
260 |b International Journal of Radiology and Radiation Oncology - Peertechz Publications,   |c 2017-01-24. 
520 |a <p>Currently, many interventionalists employ either tissue plasminogen activator (alteplase, Genentech,San Francisco, CA), or recombinant plasminogen activator (reteplase, Chiesi USA, Inc., Cary, NC), for peripheral thrombolysis. Further, combination therapy utilizing a thrombolytic agent and a glycoprotein IIb/IIIa receptor antagonist has been proposed as a way to overcome the limitations of thrombolytic therapy alone by reducing the duration of infusion, preventing rethrombosis, and improving the efficacy of thrombolysis. The following report discusses a patient with stenoses in the distal right posterior tibial artery. The patient underwent percutaneous transluminal angioplasty along with tissue plasminogen activator infusion therapy. Initially, the tissue plasminogen activator infusion reduced pain. However,an embolic occlusion to the distal right lateral plantar artery led to recurrence of pain. Due to failure of thrombolytic monotherapy using tissue plasminogen activator, a combined treatment of eptifibatide (Integrilin, Cor Therapeutics and Schering-Plough) and tissue plasminogen activator infused intraarterially was initiated. In this report, the successful clinical use of combination therapy has been demonstrated after failed intra-arterial tissue plasminogen activator infusion monotherapy. The use of purely intra-pedal intra-arterial eptifibatide is novel and should be studied in randomized trials to establish efficacy. Furthermore, we have shown that failure of monotherapy to treat occlusions can be recovered through the use of combination therapy.</p> 
540 |a Copyright © Mubin I Syed et al. 
546 |a en 
655 7 |a Case Report  |2 local 
856 4 1 |u https://doi.org/10.17352/ijrro.000020  |z Connect to this object online.